Furmonertinib is another third-generation, highly CNS-penetrant EGFR TKI that was first approved in China for the treatment of patients with locally advanced or metastatic NSCLC harboring the EGFR T790M mutation. Here, EGFR is linked to non-small cell lung carcinoma.